Posted on 6/28/19
Acer Therapeutics: Despite Receiving A Devastating CRL, The Story Isn't Over
SummaryAcer received a Complete Response Letter (CRL) from the FDA earlier this week denying approval of EDSIVO and requiring a new clinical trial be conducted.Apart from . . .
Posted on 2/12/19
Acer Therapeutics: Multiple Aces Up Its Sleeve
SummaryAcer announced on December 26, 2018 that the FDA had accepted Acer's NDA for EDSIVO for review for the treatment of vEDS.The FDA also granted priority . . .

